Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Abbott Laboratories (ABT) Insider Trading Activity

    Healthcare • Medical Devices • 114,000 employees

    Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

    Total Value

    -$68,379,701.43

    Total Shares

    88,712

    Average Trade Value

    -$1,899,436.15

    Most Active Insider

    Allen Hubert L

    Total Activity: $58,602,111

    Largest Single Transaction

    $37,435,200

    by Ford Robert B on Feb 5, 2025

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Executive Vice President
    Mar 3, 2025 791 $109,292 95,583 (-0.8%) Sale
    Executive Vice President
    Mar 3, 2025 1,111 $153,507 66,878 (-1.7%) Sale
    Retired EVP
    Mar 3, 2025 949 $131,123 74,381 (-1.3%) Sale
    Senior Vice President
    Mar 3, 2025 562 $77,652 31,970 (-1.8%) Sale
    Vice President and Controller
    Mar 3, 2025 562 $77,652 21,061 (-2.7%) Sale
    Vice President and Controller
    Feb 28, 2025 1,096 $148,914 21,623 (-5.1%) Payment of Exercise Price
    EVP and Group President
    Feb 28, 2025 8,322 $1,130,710 71,928 (-11.6%) Payment of Exercise Price
    Executive Vice President, Gc
    Feb 28, 2025 8,382 $1,138,862 191,899 (-4.4%) Payment of Exercise Price
    Executive Vice President
    Feb 28, 2025 5,598 $760,600 96,374 (-5.8%) Payment of Exercise Price
    Retired EVP
    Feb 28, 2025 7,313 $993,617 75,330 (-9.7%) Payment of Exercise Price
    Chairman and CEO
    Feb 28, 2025 31,651 $4,300,421 253,305 (-12.5%) Payment of Exercise Price
    EVP and CFO
    Feb 28, 2025 4,908 $666,850 56,553 (-8.7%) Payment of Exercise Price
    EVP and Group President
    Feb 28, 2025 8,462 $1,149,732 133,769 (-6.3%) Payment of Exercise Price
    Executive Vice President
    Feb 28, 2025 4,386 $595,926 67,989 (-6.5%) Payment of Exercise Price
    Executive Vice President
    Feb 25, 2025 22,495 $10,000 61,461 (+36.6%) Grant
    Executive Vice President
    Feb 25, 2025 10,712 $10,000 101,972 (+10.5%) Grant
    Chairman and CEO
    Feb 25, 2025 64,897 $10,000 284,956 (+22.8%) Grant
    Executive Vice President
    Feb 25, 2025 18,788 $10,000 80,250 (+23.4%) Grant
    Executive Vice President
    Feb 25, 2025 16,534 $10,000 142,231 (+11.6%) Grant
    Vice President
    Feb 25, 2025 4,038 $10,000 22,719 (+17.8%) Grant
    Executive Vice President
    Feb 25, 2025 12,278 $10,000 82,643 (+14.9%) Grant
    Executive Vice President
    Feb 25, 2025 10,232 $10,000 72,375 (+14.1%) Grant
    Executive Vice President
    Feb 25, 2025 15,475 $10,000 200,281 (+7.7%) Grant
    Chairman and CEO
    Feb 5, 2025 285,388 $10,958,899 505,447 (+56.5%) Exercise/Conversion
    Chairman and CEO
    Feb 5, 2025 285,388 $37,435,200 220,059 (-129.7%) Sale
    Executive Vice President
    Jan 30, 2025 58,428 $2,243,635 243,234 (+24.0%) Exercise/Conversion
    Executive Vice President
    Jan 30, 2025 23,771 $3,054,574 125,697 (-18.9%) Sale
    Executive Vice President
    Jan 30, 2025 23,771 $912,806 149,468 (+15.9%) Exercise/Conversion
    Executive Vice President
    Jan 30, 2025 58,428 $7,482,629 184,806 (-31.6%) Sale
    Executive Vice President
    Jan 29, 2025 131,360 $16,859,675 184,806 (-71.1%) Sale
    Executive Vice President
    Jan 29, 2025 131,360 $5,044,224 316,166 (+41.5%) Exercise/Conversion
    Executive Vice President
    Jan 28, 2025 2,644 $336,819 0 Sale
    Executive Vice President
    Oct 21, 2024 1,249 $148,394 340,978 (-0.4%) Sale
    Executive Vice President
    Oct 21, 2024 150,271 $17,578,702 184,806 (-81.3%) Sale
    Executive Vice President
    Oct 21, 2024 5,901 $697,203 335,077 (-1.8%) Sale
    Executive Vice President
    Oct 21, 2024 157,421 $7,398,787 342,227 (+46.0%) Exercise/Conversion